A SIRT6 gene therapy trial in senior beagles hit its primary endpoint, lowering biological age and offering a test bed for human medicine.

APLMS will use Singapore, China and India to test how longevity science can translate into function, prevention and healthier ...

Outer Bio’s Yuna platform keeps living human skin functioning for a month, a longer window for testing what actually slows ...

Sam Altman-backed Retro Biosciences is widening its Alzheimer’s trial after early doses showed no red flags. Most drug trials ...

New MOU pairs GlycanAge’s glycan-based biological age test with ExoEarth’s exosome platform, bringing inflammaging testing ...

New $1.08m grant aimed at the immune biology behind stem cell transplants, a research problem getting more urgent as more ...

A 350-patient study finds a palm-sized ECG device spots dangerous heart rhythms that hospital-grade monitors miss entirely.

Aesthetics empire opens its first wellness clinic, and it says something about where precision longevity in Southeast Asia is ...

Leqembi Iqlik lets patients self-administer anti-amyloid drug in about 15 seconds, cutting out the IV chair treatment used to ...

Facing a legal challenge to its sleep-tracking claims, Oura is publishing the science behind its ring, with real stakes for ...

As longevity clinics multiply and Muse cell branding proliferates, the questions patients aren't asking could cost them more than money.

Obesity biotech aims to reduce fat while preserving lean mass, with first-in-human studies planned for late 2027.